Kwonoh Park

Professor

Pusan National University Yangsan Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Kwonoh Park is a faculty member at Pusan National University Yangsan Hospital in South Korea. His research primarily focuses on oncology, particularly exploring chemotherapy efficacy, cancer pain management, and treatment regimens for urothelial carcinoma. Recent studies include the investigation of NEPA for nausea prevention in chemotherapy and the use of ketamine as an adjuvant therapy for terminally ill cancer patients. He is also involved in assessing chemotherapy protocols and opioid management for cancer patients.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kwonoh Park

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Efficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for grade 2 or higher emesis

Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08)

A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial)

Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice

Phase II study of neoadjuvant chemotherapy with four cycles of dose‐dense MVAC followed by radical cystectomy in Korean patients with muscle‐invasive or locally advanced urothelial carcinoma of bladder

Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial

Survey of Opioid Risk Tool Among Cancer Patients Receiving Opioid Analgesics

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure

Clinical Characteristics, Treatment Delivery, and Cisplatin Eligibility in Korean Patients Initially Diagnosed with Urothelial Carcinoma

Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients

Collaborators (5)

Su-Jin Koh

Jung Hun Kang

Jong Kil Nam

HYO JIN LEE

Jae Lyun Lee

Make your next move.